Linked Life Data

12804039

Source:http://linkedlifedata.com/resource/pubmed/id/12804039

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2003-6-13
pubmed:abstractText
A study was undertaken to investigate the suitability of using a high affinity (Kd = 1.1 nM) anti-CD45 monoclonal antibody for delivering the high energy beta-particle emitting isotope (90)Y to lymphohematopoietic target cells in vivo. The antibody, AHN-12, recognized the tyrosine phosphatase CD45 expressed on the surface of normal and malignant hematopoietic cells and studies showed that it reacted with both CD45-expressing normal peripheral blood cells and leukemia cells from patients. The antibody was readily labeled with (90)Y using the highly stable chelate 1B4M-DTPA and the radioimmunoconjugate was designated (90)Y-anti-CD45. The agent selectively bound to CD45(+) B cell line Daudi, but not CD45(-) control cells and significantly (p = 0.007) more bound to Daudi tumors growing in athymic nude mice than did a control non-reactive antibody. Moreover, biodistribution data correlated well to an anti-Daudi effect observed against established tumors in nude mice. The effect was dose dependent and irreversible with the best results in mice receiving a single dose of 137 microCi (90)Y-anti-CD45. These mice displayed a significantly (p < 0.0095) better anti-tumor effect than a control (90)Y-labeled antibody and survived over 135 days with no evidence of tumor. Histology studies showed no significant injury to kidney, liver, or small intestine even at 254 microCi, the highest dose tested. Because radiolabeled anti-CD45 antibody can be used to deliver radiation selectively to lymphohematopoietic tissue, these data indicate that this agent may be used to improve treatment of hematopoietic malignancies, particularly leukemia and lymphoma, when combined with hematopoietic stem cell transplantation in a future clinical trial.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1084-9785
pubmed:author
pubmed:issnType
Print
pubmed:volume
18
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
133-45
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:12804039-Animals, pubmed-meshheading:12804039-Antibodies, Monoclonal, pubmed-meshheading:12804039-Antigens, CD45, pubmed-meshheading:12804039-Burkitt Lymphoma, pubmed-meshheading:12804039-Drug Evaluation, Preclinical, pubmed-meshheading:12804039-Female, pubmed-meshheading:12804039-Hematopoietic Stem Cells, pubmed-meshheading:12804039-Humans, pubmed-meshheading:12804039-Indium Radioisotopes, pubmed-meshheading:12804039-Leukemia, Myeloid, pubmed-meshheading:12804039-Mice, pubmed-meshheading:12804039-Mice, Inbred C57BL, pubmed-meshheading:12804039-Mice, Nude, pubmed-meshheading:12804039-Pentetic Acid, pubmed-meshheading:12804039-Radioimmunotherapy, pubmed-meshheading:12804039-Tissue Distribution, pubmed-meshheading:12804039-Tumor Cells, Cultured, pubmed-meshheading:12804039-Yttrium Radioisotopes
pubmed:year
2003
pubmed:articleTitle
Preclinical studies targeting normal and leukemic hematopoietic cells with Yttrium-90-labeled anti-CD45 antibody in vitro and in vivo in nude mice.
pubmed:affiliation
University of Minnesota Cancer Center, Department of Therapeutic Radiology-Radiation Oncology, Minneapolis 55455, USA. valle001@umn.edu
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't